ArticleJournal of ovarian research2026
Anastomotic leakage after rectosigmoid resection with primary anastomosis during cytoreductive surgery for advanced high-grade serous ovarian cancer: risk factors and oncologic outcomes.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors associated with and evaluate the impact of anastomotic leakage on oncological outcomes in patients with advanced-stage (Fédération Internationale de Gynécologie et d’Obstétrique [International Federation of Gynaecology and Obstetrics], FIGO grade III–IV) high-grade serous ovarian cancer who underwent rectosigmoid resection with primary anastomosis during cytoreductive surgery. MATERIALS AND
methodsThe data of 102 patients treated between September 2015 and October 2024 at two tertiary gynaecologic oncology centres were retrospectively analyzed. Demographic, clinical, intraoperative, and postoperative parameters were reviewed. Anastomotic leakage was diagnosed on the basis of clinical, radiological, or intraoperative findings. Progression-free survival (PFS) and overall survival (OS) were analysed using the Kaplan–Meier method.
resultsRectosigmoid anastomotic leakage occurred in 9 (8.8%) patients—all of whom were surgically managed—and was not attributed to mortality. Patients with greater intraoperative blood loss, a greater number of transfused red blood cell units and lower serum albumin levels on postoperative day 1 demonstrated a significantly increased risk of anastomotic leakage. Although anastomotic leakage significantly delayed the initiation of adjuvant chemotherapy (median 39.5 days vs. 18 days), no statistically significant difference in PFS or OS was identified under the prespecified endpoint definition (time zero at completion of adjuvant chemotherapy).
conclusionRectosigmoid resection with primary anastomosis can be safely performed in patients with advanced high-grade serous ovarian cancer as part of cytoreductive surgery. Intraoperative haemorrhage, the need for perioperative transfusion, and early postoperative hypoalbuminaemia are key predictors of anastomotic leakage. Anastomotic leakage was associated with delayed initiation of adjuvant chemotherapy; however, no statistically significant difference in PFS or OS was detected under the prespecified endpoint definition. However, these survival findings should be interpreted as exploratory in light of potential guarantee-time bias and unmeasured temporal changes in systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.